RCT (n=6,558)
Double-blind
Permuted-block
Yes
Answers are grounded in this paper and cite their sources.
May warrant ivabradine consideration in chronic HF with elevated heart rate; extends randomized evidence for sinus node inhibition.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The October 2015 monograph topics are sacubitril/valsartan, daclatasvir, sonidegib, alirocumab, and sodium zirconium cyclosilicate. The Safety MUE is on sacubitril/valsartan.
No takes yet. Share an insight, caveat, or question.
Cada et al. (2015) conducted an RCT in Chronic heart failure (n=6,558). Ivabradine vs. Placebo was evaluated on Composite of first cardiovascular event leading to death or hospitalization for worsening heart failure (HR 0.82, 95% CI 0.75 to 0.9, p=<.001).
Synapse has enriched 10 related papers. Consider them for comparative context: